Breast cancer remains one of the leading causes of cancer-related deaths worldwide. For patients diagnosed with Hormone Receptor (HR)-positive and HER2-negative advanced or metastatic breast cancer, targeted therapies such as Palnat (Palbociclib) Capsules have significantly improved treatment outcomes.
Cordium Pharmaceuticals Pvt Ltd manufactures Palnat (Palbociclib) 75mg, 100mg, and 125mg Capsules, delivering high-quality oncology medicines that meet international pharmaceutical standards for global healthcare providers.
What is Palnat (Palbociclib)?
Palnat contains Palbociclib, a selective CDK4/6 inhibitor that slows the growth and division of cancer cells.
It is prescribed in combination with:
Aromatase inhibitors
Fulvestrant
Hormonal therapy
to improve progression-free survival in patients with HR+/HER2− advanced breast cancer.
Available Strengths
Cordium Pharmaceuticals offers:
Palnat 75mg Capsules
Palnat 100mg Capsules
Palnat 125mg Capsules
These dosage strengths allow oncologists to adjust therapy based on patient response and tolerability.
Indications
Palnat is indicated for:
✅ HR-positive metastatic breast cancer
✅ HER2-negative advanced breast cancer
✅ First-line endocrine therapy combination
✅ Disease progression following endocrine therapy
How Palnat Works
Palbociclib blocks Cyclin-Dependent Kinases 4 and 6 (CDK4/6), preventing cancer cells from progressing through the cell cycle.
Benefits include:
Slows tumor growth
Delays disease progression
Improves progression-free survival
Enhances effectiveness of hormone therapy
Helps maintain quality of life
Benefits of Palnat Capsules
Proven Clinical Effectiveness
Clinical studies have demonstrated that Palbociclib significantly delays cancer progression when combined with endocrine therapy.
Flexible Dosage
Available in three strengths:
75mg
100mg
125mg
allowing personalized dose adjustments.
International Manufacturing Standards
Cordium Pharmaceuticals follows stringent quality assurance systems for global pharmaceutical distribution.
Dosage and Administration
Typical dosage:
125mg once daily for 21 consecutive days followed by 7 days off treatment, completing a 28-day cycle.
Dose reductions may be recommended to:
100mg
75mg
depending on adverse effects or blood count monitoring.
Important: Treatment should always be administered under the supervision of a qualified oncologist.
Possible Side Effects
Like all cancer medicines, Palnat may cause side effects including:
Low white blood cell count (Neutropenia)
Fatigue
Hair thinning
Nausea
Mouth ulcers
Infections
Diarrhea
Reduced appetite
Routine blood monitoring is essential during therapy.
Storage Instructions
Store below 30°C.
Protect from moisture and direct sunlight.
Keep out of reach of children.
Why Choose Cordium Pharmaceuticals?
Cordium Pharmaceuticals Pvt Ltd is committed to providing affordable, high-quality oncology medicines for healthcare providers and patients worldwide.
Advantages
WHO-GMP quality manufacturing
Reliable global exports
Competitive pricing
Oncology specialization
Consistent product availability
International packaging standards
Countries We Serve
Cordium Pharmaceuticals supplies oncology medicines to healthcare distributors, hospitals, pharmacies, and importers across:
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 United Arab Emirates (UAE)
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🇺🇸 United States
🇬🇧 United Kingdom
🇿🇦 South Africa
Frequently Asked Questions (FAQs)
Is Palnat the same as Palbociclib?
Yes. Palnat contains Palbociclib, a CDK4/6 inhibitor used to treat HR+/HER2− advanced breast cancer.
What strengths are available?
Palnat is available in:
75mg
100mg
125mg Capsules
Can Palnat be used alone?
It is generally prescribed in combination with hormone therapy rather than as monotherapy.
Is Palnat used for metastatic breast cancer?
Yes. It is indicated for HR-positive, HER2-negative advanced or metastatic breast cancer.
Does Palnat require medical supervision?
Yes. Blood counts and overall treatment response should be monitored regularly by an oncology specialist.
